Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02888977 | Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALL(EWALL_OBS) | unknown | — | 100 | Versailles HospitalOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT03599869 | Management of Mixed-Phenotype Acute Leukemia in the East of France(ELABEST) | unknown | — | 70 | Central Hospital, Nancy, FranceOTHER | 0 | Jul 26, 2018 |
| clinicaltrials |
| NCT01429610 | Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia(RADICAL) | unknown | Phase 2 | 78 | Asan Medical CenterOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT03336632 | Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT | unknown | Phase 2 | 50 | Sichuan UniversityOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT03586401 | Creating a Decision Support System for the Corporate Management of Physical Therapy | unknown | — | 1,000 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT03582241 | NGS in AML Relapse(NGSAML) | unknown | — | 40 | University Hospital, Strasbourg, FranceOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT03578718 | Evaluation of the Interest of a Specialist in Dermatology for Dermatopediatric Consultations(HLSkinPed) | unknown | — | 100 | Central Hospital, Nancy, FranceOTHER | 0 | Jul 6, 2018 | clinicaltrials |
| NCT03574168 | CD19-CAR-T Cells in Patients With R/R B-ALL | unknown | Phase 1 | 40 | Bioceltech Therapeutics, Ltd.INDUSTRY | 1 | Jun 29, 2018 | clinicaltrials |
| NCT03564704 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | unknown | Phase 2 / Phase 3 | 80 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 21, 2018 | clinicaltrials |
| NCT03553238 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | unknown | Phase 2 / Phase 3 | 70 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT02576301 | Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS(AML) | unknown | Phase 1 / Phase 2 | 105 | Mateon TherapeuticsINDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02451774 | Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction(PTX-II) | unknown | Phase 2 / Phase 3 | 44 | Ramón Óscar González-Ramella, Ph.DOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT02991066 | Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia | unknown | — | 20 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | Apr 24, 2018 | clinicaltrials |
| NCT01906671 | Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid | unknown | Phase 4 | 16 | Kjeld SchmiegelowOTHER | 1 | Apr 20, 2018 | clinicaltrials |
| NCT03499912 | Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy | unknown | — | 300 | National Taiwan University HospitalOTHER | 1 | Apr 20, 2018 | clinicaltrials |
| NCT03494998 | Refining and Testing the Diagnostic Accuracy of PAT-POPS | unknown | — | 80,000 | Pennine Acute Hospitals NHS TrustOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT02744768 | D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia | unknown | Phase 2 | 60 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT01451268 | Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)(PANOBEST) | unknown | Phase 1 / Phase 2 | 62 | Johann Wolfgang Goethe University HospitalOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT03462095 | De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL) | unknown | N/A | 350 | National Research Center for Hematology, RussiaNETWORK | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03419494 | Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients | unknown | — | 40 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 5, 2018 | clinicaltrials |
| NCT03413046 | The Effect of Chemotherapy on Regulatory T Cells | unknown | — | 60 | Ankara Children's Health and Diseases Hematology and Oncology Training and Research HospitalOTHER_GOV | 0 | Jan 29, 2018 | clinicaltrials |
| NCT03408210 | Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia | unknown | N/A | 191 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03408223 | Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute Leukemia | unknown | N/A | 100 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03381781 | Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations | unknown | Phase 2 | 100 | Li JunminOTHER | 1 | Jan 4, 2018 | clinicaltrials |
| NCT02924753 | The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). | unknown | Phase 1 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 29, 2017 | clinicaltrials |
| NCT02676856 | Hematopoietic Stem Cell Microtransplantation for in AML | unknown | N/A | 40 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT03356080 | DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess | unknown | Phase 2 | 50 | Shanghai Tong Ren HospitalOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01966497 | Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia(ALFA1200) | unknown | — | 1,000 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT03337516 | Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers | unknown | N/A | 40 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 9, 2017 | clinicaltrials |
| NCT03263208 | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | unknown | Phase 1 / Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 20, 2017 | clinicaltrials |
| NCT03298828 | CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | unknown | Phase 1 | 30 | Third Military Medical UniversityOTHER | 0 | Oct 2, 2017 | clinicaltrials |
| NCT03281551 | Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma | unknown | Phase 1 | 50 | Pinze Lifetechnology Co. Ltd.INDUSTRY | 1 | Sep 15, 2017 | clinicaltrials |
| NCT03283228 | Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia | unknown | — | 30 | Assiut UniversityOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT03278145 | Dependence Receptors and Leukemia | unknown | — | 30 | Hospices Civils de LyonOTHER | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02822326 | Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia | unknown | Phase 1 | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT02345915 | Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia(LEA-JA) | unknown | N/A | 90 | Institut Paoli-CalmettesOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT01793025 | Mismatched Donor Cells to Treat Acute Myeloid Leukemia(ATAC-AML-01) | unknown | Phase 1 | 12 | Maisonneuve-Rosemont HospitalOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT03267485 | Expression of TET1 Gene in Acute Leukaemia | unknown | — | 100 | Assiut UniversityOTHER | 0 | Aug 30, 2017 | clinicaltrials |
| NCT03249636 | New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia | unknown | — | 50 | Assiut UniversityOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT03256071 | Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 90 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT02899286 | Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | unknown | Phase 2 | 25 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Jul 28, 2017 | clinicaltrials |
| NCT03148197 | Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT)(COLLECT) | unknown | — | 120 | University of CologneOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT02802267 | Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy | unknown | Phase 2 | 110 | Hybrigenics CorporationINDUSTRY | 2 | Jul 2, 2017 | clinicaltrials |
| NCT03204838 | IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients | unknown | — | 100 | Hospital General de MexicoOTHER_GOV | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01520558 | CNDO-109-AANK for AML in First Complete Remission (CR1) | unknown | Phase 1 / Phase 2 | 12 | Coronado Biosciences, Inc.INDUSTRY | 1 | Jun 29, 2017 | clinicaltrials |
| NCT03191773 | A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies | unknown | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT02660762 | Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT03114670 | Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT | unknown | Phase 1 | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT03156933 | Alternative Splicing and Leukemia Initiating Cells(ASLIC) | unknown | — | 500 | Hospices Civils de LyonOTHER | 1 | May 17, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jul 30, 2018source: clinicaltrials